Evaluation of oxidative stress, the activities of paraoxonase and arylesterase in patients with subclinic hypothyroidism

Acta Biomedica

Volumn 82, Issue 3, 2011, Pages 214-222

  Cebeci, Egemen ^a   Oner, Fatma Alibaz ^a   Usta, Murat ^b   Yurdakul, Selen ^c   Erguney, Mecdi ^a  

^a Istanbul Education and Research Hospital   (Turkey)

^b Education and Research Hospital   (Turkey)

^c FLORENCE NIGHTINGALE HOSPITAL   (Turkey)

Author keywords

Arylesterase; Atherosclerosis; Oxidative stress; Paraoxonase; Subclinical hypothyroidism

Indexed keywords

ARYLDIALKYLPHOSPHATASE; ARYLESTERASE; HIGH MOLECULAR WEIGHT LIPOPROTEIN; LIPOPROTEIN; LOW MOLECULAR WEIGHT LIPOPROTEIN; THYROTROPIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; HUMAN; MALE; OXIDATIVE STRESS; SUBCLINICAL HYPOTHYROIDISM;

ADOLESCENT; ADULT; ARYLDIALKYLPHOSPHATASE; CARBOXYLIC ESTER HYDROLASES; FEMALE; HUMANS; HYPOTHYROIDISM; MALE; MIDDLE AGED; OXIDATIVE STRESS; YOUNG ADULT;

EID: 84860815706     PISSN: 03924203     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Canaris GJ, Manowitz NR, Major G, Ridgway EC. The Colorado thyroid disease prevelance study. Arch Intern Med 2000; 160: 526-34.
2. Zulewski H, Muller B, Exer P, Miserez AR, Staub JJ. 7 Estimation of tissue hypothyroidism by a new clinical score:evaluation of patients with various grades of hypothyroidism and controls. J Clin Endocrinol Metab 1997; 82: 771-6.
3. Tanis BC, Westendorp RGJ, Smelt AHM. Effect of thyroid substitution on hypercholesterolemia in patients with subclinical hypothyroidism: a reanalysis of intervention studies. Clin Endocrinol 1996; 44: 643-9.
4. Kahaly GJ. Cardiovascular and atherogenic aspects of subclinical hypothroidism. Thyroid 2000; 10: 665-79.
5. Panese MD, Ladenson PW, Meinert CL, et al. Effect of thyroxine therapy on serum lipoproteins in patients with mild thyroid failure: a guantitative review of the literature. J Clin Endocrinol Metab 2000; 85: 2993-3001.
6. Mackness MI, Arrol S, Durrington PN. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett 1991; 286: 152-4.
7. Ekmekc̈Donma O, Ekmekçi H. Paraoksonaz Cerrahpaş Tip Dergisi. 2004; 35(2).
8. Scandinavian Simvastatin Survival Study Group. Randomised Trial Of Cholesterol Lowering n 4444 Patient With Coronary Heart Disease. Lancet 1994; 344: 1383-9.
9. Durrington PN, Mackness B, Mackness MI. Paraoxonase and Atherosclerosis. Arterioscler Thromb Vasc Biol 2001; 21: 473-80.
10. Erel O. A new automated colorimetric method for measuring total oxidant status. Clin Biochem 2005; 38: 1103-11.
11. Erel O. A novel automated method to measure total an-tioxidant response against potent free radical reactions. Clin Biochem 2004; 37: 112-9.
12. Fatourechi V. Subclinical thyroid disease. Mayo Clin Proc 2001; 76: 413-6.
13. Tunbridge WMG, Evered DC, Hall R, et al. The spectrum of thyroid disease in a community: the Whickham survey. Clin Endocrinal 1977; 7: 481-93.
14. Geul KW, Sluisveld ILL, Grobbee DE, et al. The importance of thyroid microsomal antibodies in the development of elevated serum TSH in middle aged women: Association with serum lipids. Clin Endocrimal 1993; 39: 375-80.
15. Staub JJ, Althaus BU, Engler H, et al. Spectrum of subclin-ical and overt hypothyroidism: effect on thyrotrophin, prolactin and thyroid reverse, and metabolic impact on peripheral target tissues. Am J Med 1992; 92: 631-41.
16. Bindels AJ, Westendorp RG, Forlich M, et al. The prevelance of subclinical hypothyroidism at different total plas-ma cholesterol levels in middle aged men and women: a need far case-finding? Clin Endocrinol 1999; 50: 217-220.
17. Michalopoulous G, Alevizaki M, Piperingos G, et al. High serum cholesterol levels in persons with high normal TSH levels: should one extend the definition of subclinical hypothyroidism. Fur J Endocrinol 1998; 138: 141-5.
18. Bakler SJL, Ter Matten JC, Popp-Snijders C, et al. The relationship between thyrothropin and low density lipoprotein cholesterolis modified by insulin sensitivity in healthy euthyroid subjects. J Clin Endocrinol Metab 2001; 86: 1206-11.
19. Kahaly GJ, Dillmann WH. Thyroid hormone action in the heart. Endocrine Reviews 2005; 26 704-28.
20. Fazio S, Palmieri EA, Lombardi G, Biondi B. Effects of thyroid hormone on the cardiovascular system. Recent progress in Hormone Research 2004; 59 31-50.
21. Hak AE, Pols HAP, Visser TJ, et al. Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: The Rotterdam Study. Ann Intern Med 2000; 132: 270-8.
22. Başkol G, Atmaca H, Tanriverdi F, Başkol M, Koçer C, Bayram F. Oxidative stress and enzymatic antioxidant sta-tus in patients with hypothyroidism before and after treatment. Exp Clin Endocrinol Diabetes 2007; 115 (8): 522-6.
23. Durrington PN, Mackness B, Mackness MI. The hunt for nutritional and pharmacological modulators of paraoxonase [Editorial] Arterioscler Thromb Vasc Biol 2002; 22: 1248-50.
24. Aviram M, Rosenblat M, Billecke S, et al. Human serum paraoxonase (PON1) is inactivated by oxidised low density lipoprotein and preserved by antioxidants. Free Radic Biol Med 1999; 26: 892-904.
25. Mackness MI, Arrol S, Abbott CA, Durrington PN. Protection of low-density lipoprotein against oxidative modifi-cation by highdensity lipoprotein associated paraoxonase. Atherosclerosis 1993; 104: 129-35.
26. Berliner JA, Navab M, et al. Atherosclerosis: basic mechanisms. Oxidation, inflammation, and genetics. Circulation 1995; 91: 2488-96.
27. Navab M, Hama SY, Van Lenten BJ, et al. Mildly oxidized LDL induced an increased apolipoprotein J/paraoxonase ratio. J Clin Invest 1997; 99: 2005-20.
28. Ayub A, Mackness MI, Arrol S, Mackness B, Patel J, Durrington PN. Serum paraoxonase after myocardial infarc-tion. Arterioscler Thromb Vasc Biol 1999; 19: 330-5.
29. Milionis HJ, Tambaki AB, Kanioglou CN, Elisaf MS, Tse-lepis AD, Tsatsoulis A. Thyroid substitution therapy induced high-density lipoprotein-associated platelet-activat-ing factor-acetylhyrolase in patient with subclinical hypothyroidism: a potential antiatherogenic effect. Thyroid 2005; 15 (5): 455-60.
30. Azizi F, Raiszadeh F, Solati M, Etemadi A, Rahmani M, Arabi M. Serum paraoxonase 1 activity is decreased in thy-roid dysfunction J Endocrinol Invest 2003; 26: 703-9.
31. Jayakumari N, Thejaseebai G. High prevelance of low serum paraoxonase-1 in subjects with coronary artery dis-ease. J Clin Biochem Nutr 2009; 45 (3): 278-84.
32. Şentürk T, Sarandol E, Gululu S, et al. Serum arylesterase activity is negatively correlated with inflammatory markers in patients with acute coronary syndromes. Saudi Med J 2009; 30 (3): 334-9.
33. Coria MJ, Pastran AI, Gimenez MS. Serum oxidative stress parametres of women with hypothyroidism. Acta Biomed 2009; 80 (2): 135-9.
34. Gamboa R, Regalado JC, Huesca-Gómez C, et al. Low paraoxonase and arylesterase plasma activities in Mexican patients with coronary artery disease. Arch Cardiol Mex 2008; 78 (4): 360-8.
35. Helsel G, Tatzber F, Sinzinger H. Antioxidant status in thyroid dysfunction. Clin Chem Lab Med 2002; 40 (11): 1132-4.
36. Sarandöl E, Taş S, Dirican M, Serdar Z. Oxidative stress and serum paraoxonase activity in experimental hy-poyhrodism:effect of vitamin E supplementation. Cell Biochem Funct 2005; 23 (1): 1-8.
37. Erdamar H, Demirci H, Yaman H, et al. The effect of hypothyroidism, hyperthyroidism,and their treatment on parameters of oxidative stress and antioxidant status. Clin Chem Lab Med 2008; 46 (7): 1004-10.
38. Venditti P, Balestrieri M, Di Meo S, De Leo T. Effect of thyroid state on lipid peroxidation, antioxidant defences, and susceptibility to oxidative stress in rat tissues. J Endocrinol 1997; 155 (1): 151-7.
39. Torun AN, Kulaksizoǧlu S, Kulaksizoǧlu M, Pamuk BO, İşbilen E,Tütüncü NB. Serum total antioxidant status an lipid peroxidation marker malondialdehyde levels in overt and subclinical hypothyroidism. Clin Endocrinol (Oxford) 2009; 70 (3): 469-74.
40. Hennekens C, Buring J, Manson J, Stampfer M, Rosner B, Cook N. Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasm and cardiovascular disease. N Engl J Med 1996; 334: 1145-59.
41. Catapano A, Maggi F, Tragni E. Low density lipoprotein oxidation, antioxidants, and atherosclerosis. Curr Opin Cardiol 2000; 15: 355-63.
42. Ferretti G, Bacchetti T, Moroni C, et al. Paraoxonase activity in high-density lipoproteins: a comparison between healthy and obese females. J Clin Endocrinol Metab 2005; 90 (3): 1728-33.
43. Tabur S, Torun AN, Sabuncu T, et al. Non-diabetic metabolic syndrome and obesity do not affect serum paraox-onase and arylesterase activities but do affect oxidative stress and inflammation.Eur J Endocrinol 2009 Dec 18.s